Once resistant to Roprestim/Romigrastim, will it be resistant for life?

Romiplostim is a thrombopoietin receptor agonist (TPO-RA) mainly used to treat patients with chronic immune thrombocytopenia (ITP), especially those who have failed to respond to traditional treatments. This type of drug promotes the maturation of bone marrow megakaryocytes by activating TPO receptors, thereby increasing platelet levels. With the widespread clinical application of Roprostim, the issue of its drug resistance has gradually attracted attention. In particular, if the patient's efficacy decreases after using it for a period of time, whether it means "lifelong drug resistance" has become the focus of everyone's doubts.

In fact, the "resistance" of loplastin is not equivalent to the "permanent resistance" of traditional chemotherapy drugs. In some patients, there are indeed cases where the initial response is good but the subsequent response is weakened or even the platelet count decreases, but this does not mean that all such patients will develop irreversible long-term drug resistance. Some patients may experience a weakened short-term response due to inappropriate dosage, co-infection, immune fluctuations, or other hematological diseases. At this time, the drug effect can still be restored by adjusting the dosage or using other supportive treatments.

From the perspective of immune mechanism, as a protein drug, individual patients may produce neutralizing antibodies, thereby reducing its effect. However, according to global adverse drug reaction monitoring data, this situation is not common, and even if it occurs, it may weaken over time or after drug withdrawal, causing patients to become sensitive to the drug again.

In addition, some studies have observed that some patients' hematopoietic systems gradually recovered after several months of treatment with ropruprimostat, and their platelet levels remained normal after stopping the drug, suggesting that roplastin may have "immunomodulatory" potential in some people, rather than simply relying on increasing platelets.

Reference materials:https://en.wikipedia.org/wiki/Romiplostim